Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
07 Dezembro 2023 - 3:00AM
PARIS, FRANCE, 7 December 2023 - Ipsen
(Euronext: IPN; ADR: IPSEY), a global specialty-driven
biopharmaceutical company, today holds its Capital Markets Day in
London, U.K.
“Ipsen has made significant progress since our
strategic roadmap was implemented three years ago and is today in a
great spot,” commented David Loew, Chief Executive Officer, Ipsen.
“Our business has been transformed, with the focus on Specialty
Care now supported by a stronger pipeline and momentum from our
growth platforms, as well as a robust balance sheet and an
external-innovation strategy yielding compelling results.
Ipsen is now ready for its next phase of growth
with several launches across multiple potential indications,
providing more options for patients with high unmet medical needs.
Our journey will be driven by the combination of the growth
platforms, our new medicines and more external-innovation
transactions to come. We will also continue to deliver on our
ambitious sustainability objectives and roadmap with our Generation
Ipsen program, based on Environment, Patients, People, and
Governance.
As a significantly more diversified business
across our three therapeutic areas and a geographically
well-balanced company, we now have many sustainable and attractive
growth opportunities across our portfolio and pipeline to create
long-term value for all of our stakeholders and investors.”
Strategic outlook 2027
- Several current and potential
near-term launches, including Onivyde® (irinotecan), Bylvay®
(odevixibat), elafibranor and Sohonos® (palovarotene), complemented
by many pipeline milestones over the mid term
- A strengthened and diversified
business: a combination of seven anticipated and current medicines,
each with expected peak sales of at least €500m
- A global footprint and strong
portfolio opportunity in the U.S.
- External innovation: active
business-development focus providing a platform to drive
sustainable pipeline growth
- ESG roadmap: ambitious Generation
Ipsen goals for positive change to achieve net-zero emissions by
2045 and foster Ipsen’s culture centered on patients and
society
Financial outlook
- Total-sales average growth of at
least 7% per year for the period 2023-27 and at constant exchange
rates
- Core operating margin in 2027 of at
least 32% of total sales
This outlook excludes the impact of any
potential additional late-stage1 external-innovation opportunities.
The priority for capital allocation remains focused on
external-innovation transactions across the three therapeutic areas
while maintaining net debt, including contingent liabilities, below
2.0 times EBITDA.
Agenda Today’s event will
include the following participants:
- David Loew, Chief Executive
Officer
- Aymeric Le Chatelier, Chief
Financial Officer
- Christelle Huguet, Head of
R&D
- Bartek Bednarz, Head of Global
Product & Portfolio Strategy
- Stewart Campbell, President, North
America
- Mari Scheiffele, President,
International
Event details Today’s event
will start at 12.30pm GMT, 1.30pm CET in London, with attendance by
invitation only. The event will be webcast live; all participants
will have an opportunity to ask questions and can access webcast
details here. A recording will be available on ipsen.com.
ENDS
About Ipsen We are a global
biopharmaceutical company with a focus on bringing transformative
medicines to patients in three therapeutic areas: Oncology, Rare
Disease and Neuroscience.
Our pipeline is fueled by external innovation
and supported by nearly 100 years of development experience and
global hubs in the U.S., France and the U.K. Our teams in more than
40 countries and our partnerships around the world enable us to
bring medicines to patients in more than 100 countries.
Ipsen is listed in Paris (Euronext: IPN) and in
the U.S. through a Sponsored Level I American Depositary Receipt
program (ADR: IPSEY). For more information,
visit ipsen.com.
Ipsen contacts
Investors
Craig Marks
+44 (0)7584 349 193
Nicolas Bogler
+33 6 52 19 98
92
Media
Amy Wolf
+41 79 576 07 23
Ioana
Piscociu +33
6 69 09 12 96
Disclaimers and/or
forward-looking statementsThe forward-looking statements,
objectives and targets contained herein are based on Ipsen’s
management strategy, current views and assumptions. Such statements
involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from
those anticipated herein. All of the above risks could affect
Ipsen’s future ability to achieve its financial targets, which were
set assuming reasonable macroeconomic conditions based on the
information available today. Use of the words ‘believes’,
‘anticipates’ and ‘expects’ and similar expressions are intended to
identify forward-looking statements, including Ipsen’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document
were prepared without taking into account external-growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. Ipsen must face or might
face competition from generic medicine that might translate into a
loss of market share. Furthermore, the research and development
process involves several stages each of which involves the
substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in
which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory
approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact
of pharmaceutical industry regulation and healthcare legislation;
global trends toward healthcare cost containment; technological
advances, new medicine and patents attained by competitors;
challenges inherent in new-medicine development, including
obtaining regulatory approval; Ipsen’s ability to accurately
predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of Ipsen’s patents
and other protections for innovative medicines; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Ipsen also depends on third parties to develop and market some of
its medicines which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to Ipsen’s activities and financial results. Ipsen
cannot be certain that its partners will fulfil their obligations.
It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues
than expected. Such situations could have a negative impact on
Ipsen’s business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. Ipsen’s
business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des
Marchés Financiers. The risks and uncertainties set out are not
exhaustive and the reader is advised to refer to Ipsen’s latest
Universal Registration Document, available on ipsen.com.
1 Phase III clinical development or later.
- Ipsen PR_Capital Markets Day 2023_07122023
Ipsen (EU:IPN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ipsen (EU:IPN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024